Interferon α may be back on track to treat acute myeloid leukemia

IFN-  Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo

(2014) C. Papewalis et al.   JOURNAL OF IMMUNOLOGY

CD56 marks human dendritic cell subsets with cytotoxic potential

(2013) Dessie Roothans et al.   OncoImmunology

Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation

(2012) Anaig Dagorne et al.   ANNALS OF HEMATOLOGY

Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential

(2012) Sébastien Anguille et al.   PLoS One

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interferon-α in acute myeloid leukemia: an old drug revisited

(2011) S Anguille et al.   LEUKEMIA

Induction of complete remission of acute myeloid leukaemia by pegylated interferon-α-2a in a patient with transformed primary myelofibrosis

(2009) Zwi N. Berneman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA